keyword
MENU ▼
Read by QxMD icon Read
search

Chronic spontaneous urticaria

keyword
https://www.readbyqxmd.com/read/29164723/double-blind-placebo-controlled-trial-of-the-effect-of-omalizumab-on-basophils-in-chronic-urticaria-patients
#1
Lukas Jörg, Tatjana Pecaric-Petkovic, Stephan Reichenbach, Michael Coslovsky, Odile Stalder, Werner Pichler, Oliver Hausmann
BACKGROUND: Omalizumab has been shown to be effective in treating chronic spontaneous urticaria (CSU). The reduction of FcεRI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted a double-blind, randomized, placebo-controlled trial to investigate the mode of action of omalizumab in patients with antihistamine-resistant CSU. METHODS: Thirty patients were randomized in a 2:1 ratio to receive either 300 mg omalizumab or placebo...
November 22, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29150066/treatment-with-omalizumab-or-cyclosporine-for-resistant-chronic-spontaneous-urticaria
#2
Renee Koski, Katelin K Kennedy
No abstract text is available yet for this article.
November 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29131099/the-prevalence-of-periodontitis-is-increased-in-psoriasis-and-linked-to-its-inverse-subtype
#3
Clemens Painsi, Alexander Hirtenfelder, Bernhard Lange-Asschenfeldt, Franz Quehenberger, Peter Wolf
Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors of periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. In total, data from 209 exacerbated psoriasis patients were retrospectively analyzed on recordings of periodontitis and compared with those of 91 patients with chronic spontaneous urticaria (CSU)...
November 2, 2017: Skin Pharmacology and Physiology
https://www.readbyqxmd.com/read/29130488/crp-is-linked-to-disease-activity-impact-and-response-to-treatment-in-patients-with-chronic-spontaneous-urticaria
#4
Pavel Kolkhir, Sabine Altrichter, Tomasz Hawro, Marcus Maurer
BACKGROUND: Elevated levels of C-reactive protein (CRP), a sensitive marker of inflammation, have been consistently reported in chronic spontaneous urticaria. Here, we retrospectively analyzed data from 1,253 CSU patients from two centers to answer the following questions: 1) What is the prevalence of elevated levels of CRP in CSU? 2) Why do CSU patients show elevated levels of CRP? 3) Are elevated CRP levels relevant? METHODS: Serum levels of CRP were measured by the nephelometric method...
November 12, 2017: Allergy
https://www.readbyqxmd.com/read/29129806/treatment-of-chronic-spontaneous-urticaria-immunomodulatory-approaches
#5
REVIEW
de Montjoye Laurence, Herman Anne, Nicolas Jean-François, Baeck Marie
This paper summarizes and reviews the mechanisms of action and data concerning efficacy of recommended treatments as well as other treatments that have been tested, independently of the outcomes, in the management of chronic spontaneous urticaria. Due to the central role of mast cells and histamine in the pathophysiology of this disease, H1-antihistamines remain the first-line treatment. However, current knowledge about this complex disease, also recognizes an important role for T lymphocytes, B lymphocytes, and autoantibodies...
November 9, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29128337/the-urticaria-activity-score-validity-reliability-and-responsiveness
#6
Tomasz Hawro, Tatevik Ohanyan, Nicole Schoepke, Martin Metz, Adriane Peveling-Oberhag, Petra Staubach, Marcus Maurer, Karsten Weller
BACKGROUND: Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. OBJECTIVE: To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC)...
November 8, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29102514/efficacy-and-safety-of-omalizumab-for-the-treatment-of-refractory-chronic-spontaneous-urticaria-in-japanese-patients-subgroup-analysis-of-the-phase-3-polaris-study
#7
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil
BACKGROUND: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double-blind, placebo-controlled trial in East Asian patients. However, data in Japanese patients, who have specific baseline characteristics (e.g., low angioedema incidence, different background medications) that may impact clinical outcomes, are lacking...
November 1, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29083482/the-clinical-response-to-omalizumab-in-csu-patients-is-linked-to-and-predicted-by-ige-levels-and-their-change
#8
Ragip Ertas, Kemal Ozyurt, Mustafa Atasoy, Tomasz Hawro, Marcus Maurer
BACKGROUND: Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated if response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels...
October 30, 2017: Allergy
https://www.readbyqxmd.com/read/29064119/in-chronic-spontaneous-urticaria-high-numbers-of-dermal-endothelial-cells-but-not-mast-cells-are-linked-to-recurrent-angio-oedema
#9
D Terhorst, I Koti, K Krause, M Metz, M Maurer
BACKGROUND: Chronic spontaneous urticaria (CSU) is an inflammatory skin disorder characterized by recurrent weals, angio-oedema or both. Recent studies have shown that the number of endothelial cells is increased in the skin of patients with CSU, but the underlying mechanisms and clinical implications of this are unclear. AIM: To evaluate whether mast cell (MC) or endothelial cell (EC) numbers correlate with CSU and whether they are relevant for disease duration, disease activity or the presence of clinical features...
October 24, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29058822/omalizumab-rapidly-improves-angioedema-related-quality-of-life-in-adult-patients-with-chronic-spontaneous-urticaria-x-act-study-data
#10
Petra Staubach, Martin Metz, Nadine Chapman-Rothe, Christian Sieder, Matthias Bräutigam, Marcus Maurer, Karsten Weller
BACKGROUND: The X-ACT study aims to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1 -antihistamines. METHODS: In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks...
October 23, 2017: Allergy
https://www.readbyqxmd.com/read/29044681/does-omalizumab-modify-a-course-of-recalcitrant-chronic-spontaneous-urticaria-a-retrospective-study-in-asian-patients
#11
Kanokvalai Kulthanan, Papapit Tuchinda, Chayanee Likitwattananurak, Puncharas Weerasubpong, Leena Chularojanamontri
Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Medical records of recalcitrant CSU patients who attended Siriraj Hospital between 2013 and 2017 were reviewed. All patients receiving omalizumab treatment were followed after the first injection for at least 1 year. Of 15 patients receiving omalizumab treatment, 11 patients (73...
October 17, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29038618/mediators-of-inflammation-and-angiogenesis-in-chronic-spontaneous-urticaria-are-they-potential-biomarkers-of-the-disease
#12
REVIEW
Ilaria Puxeddu, Federico Pratesi, Domenico Ribatti, Paola Migliorini
In chronic spontaneous urticaria (CSU), different pathophysiological mechanisms, potentially responsible for the development of the disease, have been recently described. It is likely that the activation of skin mast cells with consequent release of histamine and other proinflammatory mediators is responsible for vasodilation in the lesional skin of CSU. However, the underlying causes of mast cell activation in the disease are largely unknown and remain to be identified. Thus, in this review, we discuss new insights in the pathogenesis of CSU, focusing on inflammation and angiogenesis...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/29037900/autoimmune-comorbidity-in-chronic-spontaneous-urticaria-a-systematic-review
#13
REVIEW
Pavel Kolkhir, Elena Borzova, Clive Grattan, Riccardo Asero, Dmitry Pogorelov, Marcus Maurer
BACKGROUND AND OBJECTIVE: Numerous autoimmune diseases (AIDs) have been linked to chronic spontaneous urticaria (CSU). Here, we provide the first extensive and comprehensive evaluation of the prevalence of AIDs in patients with CSU and vice versa. METHODS: A Pubmed and Google Scholar search was performed to identify studies reporting the prevalence of various AIDs in CSU and vice versa published before April 2017. RESULTS: The prevalence of individual AIDs in CSU is increased (≥1% in most studies vs ≤1% in the general population)...
October 14, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28993062/chronic-spontaneous-urticaria-and-the-extrinsic-coagulation-system
#14
REVIEW
Yuhki Yanase, Shunsuke Takahagi, Michihiro Hide
Chronic spontaneous urticaria (CSU) is a common skin disorder characterized by daily or almost daily recurring skin edema and flare with itch. Recently, the activation of the blood coagulation cascade has been suggested to be involved in CSU, but the trigger of the coagulation cascade remains unclear. In this article, we review recent understanding of the relationship between the pathogenesis of CSU and extrinsic coagulation reactions. In CSU, vascular endothelial cells and eosinophils may play a role as TF-expressing cells for activating the extrinsic coagulation pathway...
October 6, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28988786/omalizumab-for-severe-chronic-spontaneous-urticaria-real-life-experiences-of-280-patients
#15
Zahava Vadasz, Yuval Tal, Menachem Rotem, Vered Shichter-Confino, Keren Mahlab-Guri, Yael Graif, Aharon Kessel, Nancy Agmon-Levin, Ramit Maoz-Segal, Shmuel Kivity, Shira Benor, Idit Lachover-Roth, Yuri Zeldin, Migel Stein, Ori Toker, Gamal Hassoun, Shira Bezalel-Rosenberg, Elias Toubi, Ilan Asher, Zev Sthoeger
No abstract text is available yet for this article.
October 4, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28983950/epidemiology-and-comorbidities-of-patients-with-chronic-urticaria-in-korea-a-nationwide-population-based-study
#16
Bo Ri Kim, Seungkeol Yang, Jee Woong Choi, Chong Won Choi, Sang Woong Youn
Few population-based studies have focused on the epidemiology and comorbidities of chronic urticaria (CU) or chronic spontaneous urticaria (CSU). The objective of this study was to obtain information on the epidemiology and comorbidities associated with CU and CSU in Korea. We conducted a cross-sectional analysis using a national health insurance database. An algorithm based on the International Classification of Diseases, 10th revision, was used for the identification of patients with CU and CSU, and an age-sex adjusted logistic regression model was used to assess the risk of comorbidities in these patients...
October 6, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28983485/anti-ige-treatment-for-disorders-other-than-asthma
#17
REVIEW
Jeffrey Stokes
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28979013/subcutaneous-autologous-serum-therapy-in-chronic-spontaneous-urticaria
#18
Kiran Vasant Godse, Nitin Nadkarni, Sharmila Patil, Aayushi Mehta
BACKGROUND: There is a felt need for trying newer therapeutic modalities in patients with chronic spontaneous urticaria, especially in the subset of patients classified as non-responders to antihistamines. Autologous serum therapy is an upcoming modality of treatment, and we decided to study its efficacy by subcutaneous route. AIMS: To evaluate the effectiveness of subcutaneous autologous serum therapy (AST) in CSU. METHODS: This was a single blind, placebo-controlled parallel group, randomized, controlled study...
September 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28973060/evaluating-comorbidities-natural-history-and-predictors-of-early-resolution-in-a-cohort-of-children-with-chronic-urticaria
#19
Elena Netchiporouk, Denis Sasseville, Linda Moreau, Youssef Habel, Elham Rahme, Moshe Ben-Shoshan
Importance: Chronic urticaria (CU) affects 0.1% to 0.3% of children. Most cases have no identifiable trigger and are classified as chronic spontaneous urticaria (CSU). At least half of patients with CSU may have an autoimmune etiology that can be determined in vitro using the basophil activation test (BAT). While 30% to 55% of CU cases resolve spontaneously within 5 years in adults, the natural history and predictors of resolution in children are not known. Objective: To assess the comorbidities, natural history of CU, and its subtypes in children and identify predictors of resolution...
September 27, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28968274/critical-appraisal-of-the-unmet-needs-in-the-treatment-of-chronic-spontaneous-urticaria-with-omalizumab-an-italian-perspective
#20
Riccardo Asero, Giorgio W Canonica, Antonio Cristaudo, Maria T Fierro, Giampiero Girolomoni, Angelo V Marzano, Eustachio Nettis, Patrizia Pepe, Paolo Pigatto, Oliviero Rossi
PURPOSE OF REVIEW: The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. RECENT FINDINGS: Although modern second-generation H1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients...
December 2017: Current Opinion in Allergy and Clinical Immunology
keyword
keyword
21212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"